Array
(
    [results] => Array
        (
            [0] => Array
                (
                    [ArticleID] => 833899
                    [Title] => Novartis cancer drug gets Phl FDA approval
                    [Summary] => 
The Novartis anti-cancer drug everolimus, in combination with aromatase inhibitor, is now approved in the Philippines for the treatment of hormone receptor-positive (HR+), HER2/neu-negative (HER2-) advanced breast cancer, in postmenopausal women after recurrence or progression following endocrine therapy.
                    [DatePublished] => 2012-08-02 00:00:00
                    [ColumnID] => 133272
                    [Focus] => 0
                    [AuthorID] => 
                    [AuthorName] => 
                    [SectionName] => Science and Environment
                    [SectionUrl] => science-and-environment
                    [URL] => 
                )

            [1] => Array
                (
                    [ArticleID] => 731565
                    [Title] => Treatment for advanced ovarian  cancer receives positive opinion
                    [Summary] => 
BASEL, Switzerland — Roche has announced that the Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion for the use of bevacizumab in combination with standard chemotherapy (carboplatin and paclitaxel) as a front-line treatment for women with advanced ovarian cancer.
                    [DatePublished] => 2011-09-29 00:00:00
                    [ColumnID] => 133272
                    [Focus] => 0
                    [AuthorID] => 
                    [AuthorName] => 
                    [SectionName] => Science and Environment
                    [SectionUrl] => science-and-environment
                    [URL] => 
                )

            [2] => Array
                (
                    [ArticleID] => 568687
                    [Title] => Roche's lung cancer drug receives positive opinion in Europe
                    [Summary] => 
Roche recently announced that the European Committee for Medicinal Products for Human Use (CHMP) has issued a positive opinion for use of erlotinib as a maintenance therapy for people with advanced non-small cell lung cancer (NSCLC) and stable disease (cancer remains largely unchanged) after initial chemotherapy.
                    [DatePublished] => 2010-04-23 00:00:00
                    [ColumnID] => 133272
                    [Focus] => 0
                    [AuthorID] => 1475655
                    [AuthorName] => LPM
                    [SectionName] => Cebu News
                    [SectionUrl] => cebu-news
                    [URL] => 
                )

            [3] => Array
                (
                    [ArticleID] => 302759
                    [Title] => ‘Exubera’ gets positive opinion from EMEA
                    [Summary] => PARIS — Sanofi-aventis announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMEA) issued a positive opinion recommending approval of Exubera (insulin human), an inhalable form of insulin, for the treatment of type 1 and type 2 diabetes.


                    [DatePublished] => 2005-10-20 00:00:00
                    [ColumnID] => 133272
                    [Focus] => 0
                    [AuthorID] => 
                    [AuthorName] => 
                    [SectionName] => Science and Environment
                    [SectionUrl] => science-and-environment
                    [URL] => 
                )

        )

)

HUMAN USE

Array
(
    [results] => Array
        (
            [0] => Array
                (
                    [ArticleID] => 833899
                    [Title] => Novartis cancer drug gets Phl FDA approval
                    [Summary] => 
The Novartis anti-cancer drug everolimus, in combination with aromatase inhibitor, is now approved in the Philippines for the treatment of hormone receptor-positive (HR+), HER2/neu-negative (HER2-) advanced breast cancer, in postmenopausal women after recurrence or progression following endocrine therapy.
                    [DatePublished] => 2012-08-02 00:00:00
                    [ColumnID] => 133272
                    [Focus] => 0
                    [AuthorID] => 
                    [AuthorName] => 
                    [SectionName] => Science and Environment
                    [SectionUrl] => science-and-environment
                    [URL] => 
                )

            [1] => Array
                (
                    [ArticleID] => 731565
                    [Title] => Treatment for advanced ovarian  cancer receives positive opinion
                    [Summary] => 
BASEL, Switzerland — Roche has announced that the Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion for the use of bevacizumab in combination with standard chemotherapy (carboplatin and paclitaxel) as a front-line treatment for women with advanced ovarian cancer.
                    [DatePublished] => 2011-09-29 00:00:00
                    [ColumnID] => 133272
                    [Focus] => 0
                    [AuthorID] => 
                    [AuthorName] => 
                    [SectionName] => Science and Environment
                    [SectionUrl] => science-and-environment
                    [URL] => 
                )

            [2] => Array
                (
                    [ArticleID] => 568687
                    [Title] => Roche's lung cancer drug receives positive opinion in Europe
                    [Summary] => 
Roche recently announced that the European Committee for Medicinal Products for Human Use (CHMP) has issued a positive opinion for use of erlotinib as a maintenance therapy for people with advanced non-small cell lung cancer (NSCLC) and stable disease (cancer remains largely unchanged) after initial chemotherapy.
                    [DatePublished] => 2010-04-23 00:00:00
                    [ColumnID] => 133272
                    [Focus] => 0
                    [AuthorID] => 1475655
                    [AuthorName] => LPM
                    [SectionName] => Cebu News
                    [SectionUrl] => cebu-news
                    [URL] => 
                )

            [3] => Array
                (
                    [ArticleID] => 302759
                    [Title] => ‘Exubera’ gets positive opinion from EMEA
                    [Summary] => PARIS — Sanofi-aventis announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMEA) issued a positive opinion recommending approval of Exubera (insulin human), an inhalable form of insulin, for the treatment of type 1 and type 2 diabetes.


                    [DatePublished] => 2005-10-20 00:00:00
                    [ColumnID] => 133272
                    [Focus] => 0
                    [AuthorID] => 
                    [AuthorName] => 
                    [SectionName] => Science and Environment
                    [SectionUrl] => science-and-environment
                    [URL] => 
                )

        )

)

abtest

Novartis cancer drug gets Phl FDA approval

August 2, 2012 - 12:00am

The Novartis anti-cancer drug everolimus, in combination with aromatase inhibitor, is now approved in the Philippines for the treatment of hormone receptor-positive (HR+), HER2/neu-negative (HER2-) advanced breast...

Science and Environment

Treatment for advanced ovarian cancer receives positive opinion

September 29, 2011 - 12:00am

BASEL, Switzerland — Roche has announced that the Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion for the use of bevacizumab in combination with standard chemotherapy (carboplatin...

Science and Environment

Roche's lung cancer drug receives positive opinion in Europe

By LPM | April 23, 2010 - 12:00am

Roche recently announced that the European Committee for Medicinal Products for Human Use (CHMP) has issued a positive opinion for use of erlotinib as a maintenance therapy for people with advanced non-small cell...

Cebu News

‘Exubera’ gets positive opinion from EMEA

October 20, 2005 - 12:00am

PARIS — Sanofi-aventis announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMEA) issued a positive opinion recommending approval of Exubera (insulin human),...

Science and Environment